127 related articles for article (PubMed ID: 28008665)
1. Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-β) via extensive ligand-based modeling and virtual screening.
Al-Sha'er MA; Almazari IS; Taha MO
J Mol Recognit; 2017 Jun; 30(6):. PubMed ID: 28008665
[TBL] [Abstract][Full Text] [Related]
2. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Taha MO; Al-Sha'er MA; Khanfar MA; Al-Nadaf AH
Eur J Med Chem; 2014 Sep; 84():454-65. PubMed ID: 25050878
[TBL] [Abstract][Full Text] [Related]
3. Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents.
Mansi I; Al-Sha'er MA; Mhaidat N; Taha M
Anticancer Agents Med Chem; 2020; 20(4):476-485. PubMed ID: 31889497
[TBL] [Abstract][Full Text] [Related]
4. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
5. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis.
Al-Sha'er MA; Al-Aqtash RA; Taha MO
Med Chem; 2019; 15(6):588-601. PubMed ID: 30799792
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Al-Sha'er MA; Khanfar MA; Taha MO
J Mol Model; 2014 Jan; 20(1):2080. PubMed ID: 24469103
[TBL] [Abstract][Full Text] [Related]
7. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.
Abuhamdah S; Habash M; Taha MO
J Comput Aided Mol Des; 2013 Dec; 27(12):1075-92. PubMed ID: 24338032
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent IRAK-4 inhibitors as potential anti-inflammatory and anticancer agents using structure-based exploration of IRAK-4 pharmacophoric space coupled with QSAR analyses.
Khanfar MA; Alqtaishat S
Comput Biol Chem; 2019 Apr; 79():147-154. PubMed ID: 30818109
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.
Shahin R; Swellmeen L; Shaheen O; Aboalhaija N; Habash M
J Comput Aided Mol Des; 2016 Jan; 30(1):39-68. PubMed ID: 26685860
[TBL] [Abstract][Full Text] [Related]
10. Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors.
Al-Sha'er MA; VanPatten S; Al-Abed Y; Taha MO
J Mol Graph Model; 2013 May; 42():104-14. PubMed ID: 23603608
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
13. In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking.
Wang JL; Li L; Hu MB; Wu B; Fan WX; Peng W; Wei DN; Wu CJ
Comput Biol Chem; 2019 Feb; 78():297-305. PubMed ID: 30605855
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques.
Noha SM; Atanasov AG; Schuster D; Markt P; Fakhrudin N; Heiss EH; Schrammel O; Rollinger JM; Stuppner H; Dirsch VM; Wolber G
Bioorg Med Chem Lett; 2011 Jan; 21(1):577-83. PubMed ID: 21078555
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation.
Al-Sha'er MA; Mansi I; Khanfar M; Abudayyh A
J Enzyme Inhib Med Chem; 2016; 31(sup4):64-77. PubMed ID: 27569779
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Al-Nadaf AH; Taha MO
J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent NEK2 inhibitors as potential anticancer agents using structure-based exploration of NEK2 pharmacophoric space coupled with QSAR analyses.
Khanfar MA; Banat F; Alabed S; Alqtaishat S
Mol Divers; 2017 Feb; 21(1):187-200. PubMed ID: 27599492
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.
Taha MO; Tarairah M; Zalloum H; Abu-Sheikha G
J Mol Graph Model; 2010 Jan; 28(5):383-400. PubMed ID: 19850503
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
Aboalhaija NH; Zihlif MA; Taha MO
Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.
Al-Sha'er MA; Taha MO
J Mol Graph Model; 2018 Aug; 83():153-166. PubMed ID: 29456101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
